Do you want to connect with more than 355,000 licensed nurse practitioners (NPs) and 121,000 members of the American Association of Nurse Practitioners® (AANP) nationwide? Would you benefit from exclusive insight into the minds of NPs as you make your business decisions?
Showcase your support for the NP role and gain access to exclusive opportunities to conduct market research and focus groups, meet with AANP leadership and utilize AANP marketing channels by becoming a member of the Corporate Council.
Know what NPs need, hear what NPs want and give yourself the tools to reach them.
Membership on the AANP Corporate Council comes with plenty of benefits — including connections to NP leaders, exclusive marketing opportunities, an industry presence at AANP’s conferences and opportunities to conduct market research. See the complete list of benefits:
Membership is subject to approval.
Abbott is a global health care leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of health care, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.
Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. Founded in 1978, Biogen today has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy and has developed the first approved treatment to address a defining pathology of Alzheimer’s disease. Biogen is also commercializing biosimilars and focusing on advancing one of the industry’s most diversified pipelines in neuroscience that will transform the standard of care for patients in several areas of high unmet need, including depression. For more information, please visit biogen.com.
Developed with dermatologists, all CeraVe products are formulated with three essential ceramides (1, 3 and 6-II) to help maintain and restore the skin's natural protective barrier, reinforcing healthy skin for all.
Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Founded in 1999 and headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom strives to simplify and improve diabetes management around the world. CGM systems are medical devices that can show patients’ glucose levels (including the rate of change and direction) throughout the day and night. Dexcom CGM reduces some of the guesswork that comes with making diabetes treatment decisions, offering our users’ greater peace of mind.
EBSCO Information Services (EBSCO) is the preeminent provider of online research content and search technologies serving academic, school, public and medical libraries. The EBSCO Clinical Decisions suite of solutions gives health care providers worldwide evidence-based peace of mind in the form of clinical decision support, shared decision-making and skill development offerings. Flagship solutions including DynaMed®, DynaMed Decisions and Dynamic Health™ are united across a familiar platform and supported by the same rigorous evidence-based methodology ensuring fast, trusted answers to clinical questions. Our mission is to improve patient care by providing health care professionals with trusted information when, where and how they need it.
At Eisai Inc., human health care (hhc) is the goal. Eisai gives its first thoughts to patients and their families and helps to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., the company has a passionate commitment to patient care that is the driving force behind its efforts to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business with discovery, clinical and marketing capabilities. Its key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us.eisai.com and follow on Twitter and LinkedIn.
Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today, our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit lilly.com and lilly.com/newsroom.
Exact Sciences Corporation (NASDAQ: EXAS) is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. As part of this mission, the company is proud to introduce Cologuard. Cologuard is an accurate, non-invasive, patient-friendly screening test that analyzes both stool DNA and blood biomarkers for the early detection of colorectal cancer and pre-cancer. Exact Sciences is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer diagnostics. Headquartered in Madison, WI., Exact Sciences employs more than 1,300 individuals in the U.S. To learn more, visit exactsciences.com.
Fullscript® is the leading online platform for practitioners to manage and dispense healthcare’s best supplements — from their clinic or directly to patients' doors.
Whether in-office or online, Fullscript helps practitioners become a safe, convenient source for trusted supplements and wellness products while easily adding a new revenue stream. Practitioners gain more control over their patients’ supplement intake and can offer savings, earn a custom profit margin, or both to grow their practices and make wellness more affordable.
The Fullscript platform also offers time-saving features, medically-reviewed resources, automated adherence tools, and more to minimize admin, grow physicians’ practices, and keep patients engaged.
GoodRx is a prescription pricing transparency and savings tool. The company believes that all Americans should have access to convenient and affordable health care. The United States spends about $3.5 trillion annually on health care, but too many people can't get the care they need and prices just keep rising. GoodRx started with prescriptions and has helped more than100 million Americans save more than $15 billion to date. GoodRx is a profitable business funded by top-tier investors. It is based in Santa Monica with additional offices around the country. The GoodRx team is a low-key, hard-working and tight-knit group that likes to find new ways to fix problems.
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division, markets a broad range of well-known and trusted over-the-counter (OTC) products. Brands include TYLENOL® and MOTRIN® pain relievers and fever reducers; BENADRYL®, ZYRTEC® and RHINOCORT® allergy medicines; IMODIUM® anti-diarrheal products; and SUDAFED® and SUDAFED PE® nasal decongestants. To learn more, visit jnj.com.
MinuteClinic is the retail medical clinic of CVS Health (NYSE: CVS), the nation’s premier health innovation company. MinuteClinic launched the first retail medical clinics in the United States in 2000 and is the largest provider of retail clinics with more than 1,000 locations in 36 states and the District of Columbia. By creating a health care delivery model that responds to patient demand, MinuteClinic makes access to high-quality health care easier for more Americans. Nationally, the company has provided care for more than 50 million patient visits since 2007, with a 95% customer satisfaction rating. The first retail health organization to receive Joint Commission accreditation back in 2006, MinuteClinic is the only retail health care provider to receive five consecutive reaccreditations. In September 2019, MinuteClinic attained Pathway to Excellence® designation from the American Nurses Credentialing Center (ANCC), becoming the first retail health care organization to receive this global credential for the organization’s commitment to creating a healthy work environment where nurses and other health care colleagues feel empowered and valued. For more information, visit minuteclinic.com.
Myriad Neuroscience, a business unit of Myriad Genetics, specializes in pharmacogenomic testing. The GeneSight® Psychotropic test, developed in the Myriad Neuroscience clinical laboratory, analyzes clinically important genetic variations that may impact how a patient metabolizes and responds to certain psychiatric medications. The results of the test provides clinicians with information about which medications may require dose adjustments, may be less likely to work, or may have an increased risk of side effects based on a patient’s genetic makeup.
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, it uses innovative science and digital technologies to create transformative treatments in areas of great medical need. In its quest to find new medicines, Novartis consistently ranks among the world's top companies investing in research and development. Novartis products reach more than 800 million people globally, and the company is finding innovative ways to expand access to its latest treatments. About 130,000 people of nearly 150 nationalities work at Novartis around the world. Novartis Pharmaceuticals Corporation, a U.S. affiliate of Novartis, is located in East Hanover, NJ. Find out more at novartis.com.
Novo Nordisk is a global health care company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases, such as obesity, as well as rare blood and rare endocrine diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat. We employ more than 50,000 people in 80 offices around the world and market our products in 170 countries. Follow Novo Nordisk on Facebook, Instagram and Twitter.
Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. The company strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with its responsibility as one of the world's premier innovative biopharmaceutical companies, Pfizer collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on it. The company routinely posts information that may be important to investors at pfizerpro.com. In addition, to learn more, please visit pfizerpro.com and follow on Twitter (@Pfizer and @Pfizer_News), LinkedIn, YouTube and Facebook (Facebook.com/Pfizer).
PhRMA represents 33 of the nation’s leading biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested nearly $1 trillion in the search for new treatments and cures, including $91.1 billion in 2020 alone. Additionally, America’s biopharmaceutical companies have successfully researched, developed, and delivered multiple vaccines and therapeutics to help halt the spread and mitigate the effects of COVID-19. PhRMA strives to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies. To accomplish this mission, the industry is dedicated to working with all stakeholders (patients, healthcare providers, policy makers) in Washington, D.C., and across the country.